The Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesity Medication

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
University of Pittsburgh
Study ID
NCT07652333
Status
Recruiting
Apply to this trial

Conditions

  • Muscle Composition
  • Obesity
  • Quality of Life (QOL)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Resistance Exercise — BEHAVIORAL
    60 min/session, all for 2 sessions/week for 12 weeks
  • GLP-1 RAs — DRUG
    Participants will take GLP-1 RAs for 12 weeks

Study Details

The purpose of this study is to examine the effects of resistance exercise, such as weightlifting, on retention of muscle mass and mental health in individuals taking GLP-1 RAs (an obesity medication). Resistance exercise is focused on increasing the strength of participants' muscles, such as how much participant can lift. •The duration of this study is 3 months. This includes: * Orientation session to explain study protocol, exercise program, and complete questionnaire about participants' medical history and lifestyle. * Two health assessments at baseline and at 3 months. These assessments include body composition, resting blood pressure, cardiovascular function, and muscular strength. Both the resistance exercise group and the control group will complete assessments at baseline and again at 3 months. After the 3-month period, individuals in the control group may choose to participate in the exercise training and complete the optional 6-month assessments. * Personalized resistance exercise sessions for 60 minutes per session, twice per week, for 3 months.

Key Dates

Start date
May 25, 2026
Status verified
Jun 2026
Primary completion
Apr 30, 2027
Completion
May 31, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Resistance Exercise (RE)
    Participants will perform 60 min of resistance exercise 2 sessions per week for 12 weeks while continuing GLP-1 RAs therapy as prescribed by regular treating provider
  • Active Comparator: Standard Care
    Participants will take GLP-1 RAs for 12 weeks as prescribed by regular treating provider

Primary Outcome Measure

Change in Body Composition [ Time Frame: From Baseline to Week 12 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Physical Activity Research Center, University of PittsburghPittsburghPennsylvania15219
Jiyeon Yoon, M.S.
[email protected]
5158174601

Find similar trials in Pittsburgh, PA

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Physical Activity Research Center, University of Pittsburgh· Pittsburgh, PA

Related Studies